A Phase 2 interventional study of Low Metformin and Mid Metformin in Type 2 Diabetes Mellitus, sponsored by NuSirt Biopharma. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-17.
Sponsored by NuSirt Biopharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 195th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2014, is one of 23 in phase 2, and was the 200th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 16 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
NuSirt Biopharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
NuSirt Biopharma has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes using HbA1c as the primary endpoint.
This is a randomized, 8-week, extension of Study NS-0100-01, to evaluate the effect of various fixed-dose (FDC) combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control.
Subjects meeting all inclusion criteria and no exclusion criteria for the extension study, including completion of the 4-week treatment period of Study NS-0100-01 [Day 28/Visit 7]), will be eligible to enroll into the extension. During participation in the extension, subjects will continue to receive their assigned treatment based upon the randomization that occurred on Day 1 (Visit 4) of Study NS-0100-0. The study will include a total of 3 visits: Visit 1E (Day 28/Visit 7 of Study NS-0100-01), Visit 2E (Day 56/Week 8), and Visit 3E (Day 84/Week 12). Key assessments at Visit 2E and Visit 3E include HbA1c, fasting plasma glucose, and plasma insulin. In addition, 3-hour standardized meal tests will be performed on Day 28 (as part of the Study Termination [Visit 7] procedures of Study NS-0100-01 prior to enrolling into the extension) and at Study Termination for the extension (Visit 3E [Day 84/Week 12]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Is male, or female and, if female, meets all of the following criteria:
Exclusion Criteria:
Subjects who meet any of the following criteria will be excluded from the study.
Is expected to require treatment, or if currently on a stable dose, changes to their regimen of the following medications:
Is expected to require or undergo treatment with any of the following medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
Drug: Low Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
Drug: Mid Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
Drug: High Metformin
3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
Drug: Metformin
1100 mg L Leucine in combination with 125 mg of Metformin BID
Also known as: Metformin, L-Leucince, Leucine
1100 mg L Leucine in combination with 250mg Metformin BID
Also known as: Metformin, Leucine, L-Leucine
1100 mg of L Leucine in combination with 500 mg Metformin BID
Also known as: Metformin, Leucine, L-Leucine
500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
Also known as: Metformin, Leucine, L-Leucine
Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations
Change in HbA1c from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy.
Time frame: Baseline and 12 weeks
Change in Fasting Plasma Glucose
Change in fasting plasma glucose from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E). Based on the pre-specified mixed model inferential statistical analysis, there was an apparent dose-dependent relationship for the mean decrease from baseline in fasting plasma glucose for the fixed dose leucine amd metformin combination treatments A, B and C.
Time frame: Baseline and 12 weeks
Study NS-0100-01E was a randomized, double-blind 8-week extension of Study NS-0100-01 to evaluate the effect of various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control.
| Milestone | FDC 125 | FDC 250 | FDC 500 | Control |
|---|---|---|---|---|
| Started | 12 | 16 | 11 | 11 |
| Completed | 10 | 15 | 11 | 11 |
| Not completed | 2 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
Change in HbA1c from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy.
| percent HbA1c | FDC 125 | FDC 250 | FDC 500 | Control |
|---|---|---|---|---|
| Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations | 0.10 ± 0.756 | -0.12 ± 0.987 | -0.05 ± 0.807 | -0.83 ± 0.627 |
Change in fasting plasma glucose from Baseline (Day 1/Visit 1) of Study NS-0100-01 to Week 12 (Day 84/Visit 3E). Based on the pre-specified mixed model inferential statistical analysis, there was an apparent dose-dependent relationship for the mean decrease from baseline in fasting plasma glucose for the fixed dose leucine amd metformin combination treatments A, B and C.
| mg/dL | FDC 125 | FDC 250 | FDC 500 | Control |
|---|---|---|---|---|
| Change in Fasting Plasma Glucose | -15.8 ± 22.29 | 11.2 ± 22.37 | -4.3 ± 39.91 | -36.3 ± 45.47 |
Collected over 84 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FDC 125 | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| FDC 250 | 0/16 (0%) | 1/16 (6.3%) | 2/16 (12.5%) |
| FDC 500 | 0/11 (0%) | 0/11 (0%) | 2/11 (18.2%) |
| Control | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Event | FDC 125 | FDC 250 | FDC 500 | Control |
|---|---|---|---|---|
| Chest PainCardiac disorders | 0/12 | 1/16 | 0/11 | 0/11 |
| Event | FDC 125 | FDC 250 | FDC 500 | Control |
|---|---|---|---|---|
| musculoskeletalMusculoskeletal and connective tissue disorders | 0/12 | 0/16 | 2/11 | 0/11 |
| Respiratory dsordersRespiratory, thoracic and mediastinal disorders | 2/12 | 1/16 | 0/11 | 0/11 |
| CoughGeneral disorders | 2/12 | 0/16 | 0/11 | 0/11 |
| Gastric DisordersGastrointestinal disorders | 0/12 | 2/16 | 1/11 | 0/11 |
| Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders | 0/12 | 2/16 | 0/11 | 0/11 |
| DiarrhoeaGeneral disorders | 0/12 | 1/16 | 0/11 | 1/11 |
| EcchymosisGeneral disorders | 1/12 | 0/16 | 1/11 | 0/11 |
| EndocrineEndocrine disorders | 1/12 | 1/16 | 0/11 | 0/11 |
| HyperglycemiaEndocrine disorders | 1/12 | 1/16 | 0/11 | 0/11 |
| FatigueGeneral disorders | 0/12 | 1/16 | 0/11 | 0/11 |
Study NS-0100-01E was the extension of Study NS-01-0100 designed to assess safety and longer term effect (ie, additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes.
| Age, Categorical(Participants) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 13 | 8 | 9 | 40 |
| >=65 years | 2 | 3 | 3 | 2 | 10 |
| Age, Continuous(years) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 51.8 ± 10.81 | 56.1 ± 8.24 | 59.8 ± 9.01 | 60.5 ± 8.77 | 56.9 ± 9.52 |
| Sex: Female, Male(Participants) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| Female | 8 | 8 | 6 | 7 | 29 |
| Male | 4 | 8 | 5 | 4 | 21 |
| Ethnicity (NIH/OMB)(Participants) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 8 | 2 | 4 | 19 |
| Not Hispanic or Latino | 7 | 8 | 9 | 7 | 31 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 5 | 4 | 13 |
| White | 10 | 13 | 6 | 7 | 36 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Weight(kg) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 93.343 ± 19.0179 | 91.314 ± 18.7664 | 87.497 ± 21.2259 | 90.500 ± 18.4163 | 90.782 ± 18.8230 |
| Body Mass Index (BMI)((kg/m^2) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 33.298 ± 4.4952 | 31.647 ± 6.3242 | 28.627 ± 4.5195 | 32.677 ± 5.3808 | 31.606 ± 5.4597 |
| Fasting Plasma Glucose(mg/dL) | FDC 125 | FDC 250 | FDC 500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 173.5 ± 31.13 | 150.5 ± 26.78 | 179.2 ± 36.04 | 177.1 ± 53.67 | 168.2 ± 38.00 |
2 further baseline measures are reported on the registry.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Oct 2014, a primary completion of Sep 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2017, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
NuSirt Biopharma